Orforglipron FDA Approval Timeline
As of April 2026, Orforglipron has not yet received FDA approval [1]. Eli Lilly anticipates submitting its new drug application to the FDA in the first half of 2024 [2].
What is Orforglipron?
Orforglipron is an oral non-peptide small molecule drug being developed for the treatment of obesity and type 2 diabetes [3]. It is a novel glucagon-like peptide-1 (GLP-1) receptor agonist [4].
How Does Orforglipron Work?
Orforglipron activates the GLP-1 receptor, mimicking the effects of the GLP-1 hormone. This action helps to regulate appetite and improve glycemic control [4]. Unlike injectable GLP-1 receptor agonists, Orforglipron is taken orally, offering a different administration route [3].
What are the Latest Clinical Trial Results?
In studies, Orforglipron has demonstrated significant weight loss in participants with overweight or obesity, and improved glycemic control in those with type 2 diabetes [3][5]. Phase 2b trials showed that participants treated with Orforglipron achieved substantial reductions in body weight and HbA1c levels [5]. Eli Lilly is currently conducting Phase 3 trials, known as the SURMOUNT program, to further evaluate its efficacy and safety [2].
When Can Patients Expect Orforglipron to Be Available?
While Eli Lilly submitted its new drug application to the FDA in the first half of 2024, the exact approval date is not yet determined. Following submission, the FDA reviews the application, which can take several months. Therefore, patient access would likely be after the FDA's decision, potentially in late 2024 or 2025, depending on the review timeline and any potential advisory committee meetings [1][2].
What Other Drugs are Similar to Orforglipron?
Orforglipron belongs to the class of GLP-1 receptor agonists. Other prominent drugs in this class include semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) [4]. These existing medications are primarily available as injectables and are used for weight management and type 2 diabetes treatment [4]. Orforglipron's key differentiator is its oral formulation [3].
What are the Potential Side Effects of Orforglipron?
Common side effects observed in clinical trials for Orforglipron include gastrointestinal issues such as nausea, diarrhea, and vomiting, similar to other GLP-1 receptor agonists [3][5]. Eli Lilly is continuing to monitor for safety and tolerability in its ongoing Phase 3 studies [2].
Who is Developing Orforglipron?
Orforglipron is being developed by Eli Lilly and Company [2].
Are There Patents for Orforglipron?
Information regarding the specific patent status and expiry dates for Orforglipron is typically detailed in patent databases. DrugPatentWatch.com provides comprehensive patent information on pharmaceutical products [6].
Sources
1. DrugPatentWatch.com
2. Eli Lilly and Company Investor Relations.
3. DrugPatentWatch.com
4. DrugPatentWatch.com
5. DrugPatentWatch.com
6. DrugPatentWatch.com